Tirzepatide 7.5 mg cost
What tirzepatide costs at the 7.5 mg dose (a mid-range titration dose) — compounded flat pricing vs brand-name self-pay tiers.
Tirzepatide 7.5 mg cost in 2026
7.5 mg is a mid-range step on the way toward a maintenance dose. This is where brand-name self-pay tiers begin to matter, since the $449 LillyDirect price requires the 45-day refill window. Compounded flat-rate pricing is identical at this dose; brand-name self-pay differs.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| NexLife Flat-rate option | Compounded, flat | $186/mo* | Not FDA-approved |
| Zepbound® LillyDirect (7.5 mg, within 45-day window) | Brand vial | $449/mo | FDA-approved |
| Zepbound® standard self-pay (7.5 mg, window missed) | Brand vial | $599/mo | FDA-approved |
| Brand retail (any dose) | Brand pen | ~$1,086/mo | FDA-approved |
Verified June 2026. At 7.5 mg, compounded flat pricing stays at $186 while brand self-pay is $449–$599. See the full price-by-dose guide.
What to know at 7.5 mg
7.5 mg is a mid-range step on the way toward a maintenance dose. This is where brand-name self-pay tiers begin to matter, since the $449 LillyDirect price requires the 45-day refill window. Your clinician sets the titration schedule based on tolerance and response; side effects (mostly mild GI symptoms) are usually most noticeable when stepping up to a new dose. Compounded tirzepatide is not FDA-approved, and eligibility is determined by a licensed clinician. See safety & eligibility.
Questions
How much does 7.5 mg tirzepatide cost?
Compounded flat-rate pricing is $186/month at 7.5 mg; brand-name Zepbound self-pay is about $449/month within LillyDirect's 45-day window (up to $599 otherwise). Compounded is not FDA-approved. See NexLife pricing
Is 7.5 mg a maintenance dose?
Maintenance doses are typically higher (often 10–15 mg) and chosen by your clinician after titration. Your schedule is individualized.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.